TD Asset Management Inc Grows Stake in Eli Lilly and Company $LLY

TD Asset Management Inc raised its stake in Eli Lilly and Company (NYSE:LLY) by 30.6% during the fourth quarter, HoldingsChannel reports. The fund owned 1,184,182 shares of the company’s stock after buying an additional 277,600 shares during the period. Eli Lilly and Company comprises approximately 1.0% of TD Asset Management Inc’s holdings, making the stock its 23rd largest position. TD Asset Management Inc’s holdings in Eli Lilly and Company were worth $1,272,617,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of LLY. Maryland Capital Advisors Inc. purchased a new stake in shares of Eli Lilly and Company during the fourth quarter valued at $25,000. Vermillion & White Wealth Management Group LLC boosted its position in shares of Eli Lilly and Company by 84.2% during the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after buying an additional 16 shares during the last quarter. 10Elms LLP boosted its position in shares of Eli Lilly and Company by 33.3% during the third quarter. 10Elms LLP now owns 40 shares of the company’s stock valued at $31,000 after buying an additional 10 shares during the last quarter. E Fund Management Hong Kong Co. Ltd. boosted its position in shares of Eli Lilly and Company by 342.9% during the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after buying an additional 24 shares during the last quarter. Finally, Miller Global Investments LLC purchased a new stake in shares of Eli Lilly and Company during the fourth quarter valued at $33,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly reported encouraging progress on its obesity and cardiometabolic pipeline, including updates on retatrutide, reinforcing confidence that the company has multiple blockbuster weight-loss drugs in development. Article Title
• Positive Sentiment: The company is also highlighting broader pipeline strength in hematology, with upcoming EHA data presentations and acquisition-related assets that could diversify revenue beyond obesity drugs. Article Title
• Positive Sentiment: Lilly signed a $1.9 billion partnership with Ascidian Therapeutics to develop RNA-based kidney disease treatments, signaling a push into new high-value therapeutic areas and supporting the “not just a weight-loss stock” thesis. Article Title
• Positive Sentiment: Commentary around more M&A, including Lilly’s dealmaker saying investors should expect additional acquisitions, may be lifting sentiment by pointing to further pipeline expansion funded by GLP-1 cash flow. Article Title
• Neutral Sentiment: Several opinion pieces and stock-prediction articles compared Lilly favorably with other names, reinforcing positive investor perception but not adding new fundamental news. Article Title
• Neutral Sentiment: Industry roundup articles and broader pharma coverage were mostly watchlist items, with little direct impact on Lilly’s near-term fundamentals. Article Title
• Negative Sentiment: Lilly also drew attention for its ultimatum to 340B hospitals to share claims data or risk losing discounts, which could create friction with providers and add some policy-related overhang. Article Title
• Negative Sentiment: One article noted the Ascidian deal announcement was followed by a modest stock decline, suggesting some traders may be cautious about deal costs even if the strategic rationale looks strong. Article Title

Eli Lilly and Company Stock Up 1.6%

NYSE LLY opened at $1,081.34 on Thursday. The stock’s 50-day moving average price is $965.78 and its 200-day moving average price is $1,011.48. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,149.10. The company has a market capitalization of $1.02 trillion, a P/E ratio of 38.41, a price-to-earnings-growth ratio of 1.16 and a beta of 0.53.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. During the same quarter last year, the company earned $3.34 earnings per share. The business’s revenue for the quarter was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities research analysts predict that Eli Lilly and Company will post 35.8 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is 24.58%.

Analyst Upgrades and Downgrades

LLY has been the topic of several recent analyst reports. The Goldman Sachs Group reaffirmed a “buy” rating and set a $1,283.00 price objective on shares of Eli Lilly and Company in a research report on Friday, May 22nd. Jefferies Financial Group raised their target price on Eli Lilly and Company from $1,300.00 to $1,330.00 in a research report on Thursday, May 21st. UBS Group reissued a “buy” rating on shares of Eli Lilly and Company in a research report on Wednesday, March 18th. Weiss Ratings cut Eli Lilly and Company from a “buy (b)” rating to a “buy (b-)” rating in a research report on Tuesday, May 19th. Finally, Truist Financial reissued a “buy” rating on shares of Eli Lilly and Company in a research report on Monday, February 23rd. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $1,227.00.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.